Company intelligence / Profile preview
Nykode Therapeutics
Oslo, Norwaynykode.com ↗
- Ownership
- Public · NYKD
- Employees
- ~139
- Development stage
- Phase 2
01
Overview
Lead candidate VB10.16 is in Phase 2 clinical trials for HPV16-positive cancers. VB10.NEO is in Phase 1b trials for locally advanced and metastatic tumors.
- Therapeutic areas
- OncologyImmunologyInfectious Diseases
- Modalities
- ImmunotherapiesTherapeutic vaccinesDNA-based immunotherapy
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
04
Financials
- Market cap
- $124.2M
- Total revenue
- $0
- Enterprise value
- $80.9M
Beyond the preview
Go deeper on Nykode Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nykode Therapeutics.